Drug intelligence / Profile preview

Nicotrol NS

Development stage: Phase 4
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intranasal

Overview

Nicotrol NS is a nicotine nasal spray formulation being investigated as an add-on therapy for motor and non-motor symptoms in patients with intermediate-stage Parkinson's disease. Developed for this indication by El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, the drug delivers nicotine in a pulsatile manner to stimulate central nicotinic acetylcholine receptors (nAChRs). This pulsatile delivery is hypothesized to be more effective than continuous delivery (like patches) by mimicking the nicotine kinetics of smoking, which epidemiological studies suggest has a neuroprotective effect against Parkinson's disease. The formulation contains 10 mg/mL of nicotine, delivering 0.5 mg per spray.

Brand names: Nicotrol NS
Other names: nicotine nasal spraytransnasal nicotine

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on Nicotrol NS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicotrol NS.